BiotechTube
Avation Medical

Avation Medical

Columbus, United States· Est.
avation.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $10M

Overview

Avation Medical is a commercial-stage private company that has successfully launched the Vivally® System, a first-in-class wearable neuromodulation device for Overactive Bladder (OAB). The system combines a closed-loop transcutaneous tibial nerve stimulation (TTNS) device worn on the ankle with a companion digital app for a holistic at-home treatment regimen. With FDA clearance, clinical validation, and an active commercial rollout supported by a customer care team, Avation is positioned to address a significant unmet need in a large, underserved market of approximately 42 million affected adults in the US.

UrologyOveractive BladderUrinary Incontinence

Technology Platform

Physiologic Closed-Loop Transcutaneous Tibial Nerve Stimulation (PCL TTNS) with continuous EMG sensing and a companion digital health application for at-home neuromodulation therapy.

Funding History

1
Total raised:$10M
Series A$10M

Opportunities

The primary opportunity is addressing the large, underserved market of ~42 million US adults with OAB who are dissatisfied with first-line drug therapies.
Vivally's at-home, wearable format offers a convenient and effective second-line option that can capture significant market share from both pharmaceuticals and more invasive procedures.
The closed-loop technology platform also presents future opportunities for expansion into other indications treatable by peripheral neuromodulation.

Risk Factors

Key risks include commercial execution challenges in securing widespread insurance reimbursement and driving physician adoption against established competitors.
The company also faces technology adoption risk, as patient compliance with at-home wearable regimens can be variable, and competitive risks from both pharmaceutical incumbents and other neuromodulation device companies.

Competitive Landscape

Avation competes in the OAB treatment market against first-line oral pharmaceuticals (e.g., anticholinergics, beta-3 agonists), other neuromodulation devices like in-office PTNS systems (e.g., Uroplasty's Urgent® PC) and implantable sacral neuromodulators (e.g., Medtronic's InterStim™, Axonics' r-SNM system), and behavioral therapies. Vivally's key competitive differentiation is its unique closed-loop, at-home wearable format, positioning it as a convenient and effective middle-ground between drugs and implants.

More companies in Digital Health & Biotech SaaS →More companies in United States →